Presence of Macrotroponin for Over 2 Years in a Young Woman

Ghossein, Jamie; Ghossein, Jason; Booth, Ronald A.; Kavsak, Peter A.; Chamoun, Chamoun

doi:10.1016/j.cjco.2022.07.016

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In healthy patients, interferences related to macrotroponin with cTn assays is possible and explained by the presence of anti‐troponin antibodies that interact with normal levels of circulating cTn (Figure 4A , Data S7 and Figure S4 ) which can lead to increased cTn results over several years. 44 , 65 Some cases of macrotroponin are also reported in the pediatric population. 66 , 67 In healthy patients, the level of hs‐cTn is generally slightly but significantly increased and stable on serial measurements, due to the slow clearance of the macrotroponin complexes.…”

Section: Troponin Antitroponin Antibodies and Macrotroponin In Routin...mentioning

confidence: 99%

Role of Antitroponin Antibodies and Macrotroponin in the Clinical Interpretation of Cardiac Troponin

Salaun,

Drory,

Coté

et al. 2024

JAHA

View full text Add to dashboard Cite

Cardiac troponin is extensively used as a biomarker in modern medicine due to its diagnostic capability for myocardial injury, as well as its predictive and prognostic value for cardiac diseases. However, heterophile antibodies, antitroponin antibodies, and macrotroponin complexes can be observed both in seemingly healthy individuals and patients with cardiac diseases, potentially leading to false positive or disproportionate elevation of cTn (cardiac troponin) assay results and introducing discrepancies in clinical interpretations with impact on medical management. In this review article, we describe the possible mechanisms of cTn release and the sources of variations in the assessment of circulating cTn levels. We also explore the pathophysiological mechanisms underlying antitroponin antibody development and discuss the influence exerted by macrotroponin complexes on the results of immunoassays. Additionally, we explore approaches to detect these complexes by presenting various clinical scenarios encountered in routine clinical practice. Finally, unsolved questions about the development, prevalence, and clinical significance of cardiac autoantibodies are discussed.

show abstract